Company intelligence / Profile preview
Kivu Bioscience
San Francisco, CA, United Stateskivubioscience.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Kivu Bioscience is advancing a pipeline of next-generation antibody-drug conjugates using proprietary site-specific conjugation technologies designed to improve the stability, homogeneity, and therapeutic window of ADC therapies. Their approach aims to reduce off-target toxicity and address limitations seen with current marketed ADCs. The company has raised $92 million Series A financing led by Novo Holdings to bring its first two lead candidates into clinical trials starting in 2025. Early data suggest superior construct stability compared to prior generations.
- Therapeutic areas
- OncologyOther
- Modalities
- Antibody-drug conjugates (ADCs)Topo1i-based ADCs (topoisomerase I inhibitor payloads)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Synaffix/Lonza – licensing agreement for GlycoConnect™ site-specific conjugation platform used as core enabling technology for their proprietary linker-payload system.
Beyond the preview
Go deeper on Kivu Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kivu Bioscience.